During the past decade, Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 16 clinical trials were completed, i.e. on average, 400% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov" #1 sponsor was "Celgene" with 7 trials, followed by "Gilead Sciences" with 5 trials sponsored, "Actelion" with 4 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "AMAG Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Chinese Hypertension League" with 1 trials as a collaborator, "European Society of Hypertension" with 1 trials as a collaborator, "Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation" with 1 trials as a collaborator and "Pharmacyclics LLC." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov" are "Pulmonary Arterial Hypertension" (4 trials), "Type 2 Diabetes Mellitus" (3 trials), "Indolent Non-Hodgkin's Lymphomas" (2 trials), "Mantle Cell Lymphoma" (2 trials) and "Myelofibrosis" (2 trials). Many other conditions were trialed in "Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov" in a lesser frequency.

Most popular intervention types in "Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov" are "Drug" (24 trials), "Behavioral" (3 trials), "Device" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Diet" (3 trials), "Exercise" (3 trials), "Lenalidomide" (3 trials) and "Ranolazine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov" are 24 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 14 completed trials in Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".